INTELLIGENT BIO SOLUTIONS INC.(INBS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $3.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
INBS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for INTELLIGENT BIO SOLUTIONS INC. (INBS), a Healthcare sector company. INBS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $3.1m in revenue. Based on the latest XBRL financial filings (Q3 2026), INTELLIGENT BIO SOLUTIONS INC. reports quarterly revenue of $1.1M, net income of $-2.9M, free cash flow of $-4.3M. Top institutional holders of INBS by reported 13-F value include ARMISTICE CAPITAL,, Alyeska Investment Group, L.P., GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. INBS trades on the Nasdaq exchange and files with the SEC under CIK 1725430. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INBS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INTELLIGENT BIO SOLUTIONS INC. directly from SEC EDGAR.
Revenue
Q3 2026
$1.1M
Net Income
Q3 2026
$-2.9M
Free Cash Flow
Q3 2026
$-4.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+142.9% YoYNet Income
+0.6% YoYOperating Income
+15.5% YoYEPS (Diluted)
+98.1% YoYTotal Assets
-20.3% YoYOp. Cash Flow
-31.2% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $3.1M +142.9% | $1.3M +187.5% | $437.1K -77.9% | $2.0M +949.3% | $188.7K | — |
| Net Income | $-10.6M +0.6% | $-10.6M -28.0% | $-8.3M -18.0% | $-7.0M -122.4% | $-3.2M | — |
| Operating Income | $-10.6M +15.5% | $-12.6M -51.1% | $-8.3M -49.6% | $-5.6M -95.1% | $-2.9M | — |
| EPS (Diluted) | $-2.00 +98.1% | $-105.83 -1020.9% | $-9.44 | — | — | — |
| Total Assets | $8.2M -20.3% | $10.4M -16.2% | $12.4M -43.5% | $21.9M +783.0% | $2.5M | — |
| Operating Cash Flow | $-9.7M -31.2% | $-7.4M -119.7% | $-3.4M +70.3% | $-11.3M -2165.6% | $-498.6K | — |
AI Insight: INBS Ratio Trends
INBS remains deeply unprofitable with negative returns across all profitability metrics; modest Q4 2025 improvement masks persistent underlying losses.
• ROE improved from -199.0% in Q1 2025 to -96.5% in Q4 2025, then declined to -127.8% in Q1 2026.
• ROA showed marginal improvement from -91.6% in Q3 2024 to -60.7% in Q4 2025, but deteriorated to -77.0% in Q1 2026.
• D/E leverage rose from 0.20 in Q2 2024 to 0.55 in Q2 2025, doubling within one year.
⚠ Q4 2025 ROIC at -95.0% represents first calculated ROIC; persistent deep-negative returns signal value destruction.
⚠ Leverage spike (0.20→0.55 YoY) alongside negative returns raises debt sustainability concerns if losses persist.
Get alerted when INBS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for INTELLIGENT BIO SOLUTIONS INC. including:
Top Institutional Holders of INBS
ARMISTICE CAPITAL, LLC
$434.9K130,000 shAlyeska Investment Group, L.P.
$127.0K37,956 shGEODE CAPITAL MANAGEMENT, LLC
$95.7K28,609 shVANGUARD CAPITAL MANAGEMENT LLC
$19.4K5,810 shVANGUARD FIDUCIARY TRUST CO
$13.2K3,958 shTower Research Capital LLC (TRC)
$4.2K1,250 shUBS Group AG
$1.2K372 shOSAIC HOLDINGS, INC.
$670.00200 shCURIO WEALTH, LLC
$669.00200 sh
| Fund | Value | Shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | $434.9K | 130,000 |
| Alyeska Investment Group, L.P. | $127.0K | 37,956 |
| GEODE CAPITAL MANAGEMENT, LLC | $95.7K | 28,609 |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.4K | 5,810 |
| VANGUARD FIDUCIARY TRUST CO | $13.2K | 3,958 |
| Tower Research Capital LLC (TRC) | $4.2K | 1,250 |
| UBS Group AG | $1.2K | 372 |
| OSAIC HOLDINGS, INC. | $670.00 | 200 |
| CURIO WEALTH, LLC | $669.00 | 200 |
More Healthcare Companies
View all Healthcare →Put INBS on your watchlist
Track score changes the day INTELLIGENT BIO SOLUTIONS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INBS a good stock to buy?
13F Pro's AI-powered analysis of INTELLIGENT BIO SOLUTIONS INC. (INBS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INBS are available on the INBS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own INBS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INBS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INTELLIGENT BIO SOLUTIONS INC.'s investment landscape.